NeoGenomics Inc. ((NEO)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NeoGenomics Inc.’s latest earnings call struck a confident tone, as management emphasized sustained double‑digit revenue growth, robust traction in next‑generation sequencing and expanding profitability. While executives acknowledged pressures from weaker nonclinical demand, near‑term gross margin headwinds and future refinancing needs, they argued that accelerating NGS adoption and new product launches leave the company on a solid upward trajectory.
Top-Line Revenue Growth
NeoGenomics reported first‑quarter revenue of $186.7 million, up 11% year over year and ahead of guidance, underscoring healthy demand across its testing portfolio. Clinical revenue was the primary engine at $171.2 million, rising 14% from a year ago and signaling continued share gains in the oncology diagnostics market.
Strong NGS Performance and Mix Shift
Next‑generation sequencing was the standout, with NGS revenue climbing 26% year over year on 16% volume growth and higher pricing. NGS now accounts for roughly one‑third of clinical revenue and is growing three to four times faster than the core clinical business, improving the company’s mix toward higher‑value testing.
Improved Profitability Metrics
Profitability trended in the right direction, with adjusted EBITDA rising 27% year over year to $9 million despite some cost headwinds. The adjusted EBITDA margin expanded by about 60 basis points, showing that NeoGenomics is beginning to scale operating leverage as volumes and NGS adoption increase.
AUP and Volume Momentum
Pricing and volume both contributed to growth as average unit price increased 8% and overall volumes grew 6% versus last year. Same‑store revenue reached $167.9 million, up 12%, driven by a 3% volume lift and 9% AUP growth, reflecting a mix shift toward more complex and better‑reimbursed tests.
Product and Reimbursement Catalysts
New products and reimbursement wins featured prominently, led by the full launch of RaDaR ST, which can detect disease down to one part per million. MolDX reimbursement for PanTracer Liquid, approved in March, positions the liquid biopsy platform to contribute mid‑single‑digit millions of revenue as physicians adopt it in routine practice.
Early Adoption Signals for RaDaR ST
Early indicators for RaDaR ST are encouraging, with about 29% of prior RaDaR 1.0 customers already ordering the new assay. Roughly 34% of RaDaR ST orders bundled additional NeoGenomics tests, and all results have been delivered faster than published turnaround times, highlighting cross‑sell potential and operational execution.
Raised 2026 Revenue Guidance
Management’s confidence was underscored by an increase in full‑year 2026 revenue guidance to a range of $797 million to $803 million. The updated outlook tightens quarterly expectations to about 9% growth in the second quarter, 9% to 10% in the third quarter and more than 10% in the fourth, suggesting accelerating momentum through the year.
Cash Flow and Liquidity Improvement
Cash generation is moving in the right direction, with cash used in operations improving to $8.1 million from roughly $25.3 million a year ago. NeoGenomics closed the quarter with $146 million in cash and management expects to be free cash flow positive for the year, providing more flexibility to fund growth initiatives.
Commercial and Operational Investments
To support adoption of RaDaR ST and PanTracer, the company plans to add about 25 sales resources by the third quarter. The Pathline acquisition has strengthened NeoGenomics’ footprint in the Northeast, which is growing at one and a half times the national average, while roughly 330 interfaces, including Epic Aura, are being deployed to make ordering easier.
Pipeline and R&D Progress
NeoGenomics is investing selectively in research and development, including whole genome sequencing and a next‑generation minimal residual disease platform targeted for potential launch as early as 2028. The company also expanded its nonclinical menu with offerings such as an AML flow panel and new IHC markers, aimed at broadening its technology base.
Nonclinical Revenue Weakness
Not all segments are moving in sync, as nonclinical revenue fell 15% year over year to $15.5 million, reflecting expected softness in pharma services. Management guided that nonclinical revenue will likely remain under pressure, forecasting low‑ to mid‑single‑digit declines for 2026 even as other parts of the business grow.
Gross Margin Pressure in Q1
Margins faced a temporary squeeze, with adjusted gross margin at 46%, down about 80 basis points from last year. Roughly 150 basis points of headwind stemmed from the dilutive impact of the Pathline acquisition and launching PanTracer Liquid ahead of reimbursement approval, compounded by higher freight and fuel costs tied to geopolitical factors.
Payer and Reimbursement Uncertainty
Management cautioned that commercial payer coverage for newer liquid biopsy offerings and RaDaR ST will take time to mature. Initial payment mix and timing remain uncertain, particularly where Medicare exposure is high, putting some pressure on near‑term monetization until broader commercial coverage ramps.
Residual Impact from Low-Value Contracts and Weather
The company is still working through residual effects from strategically exiting a high‑volume, low‑value contract that represented about 3% to 4% of volumes. Severe weather, especially in the Northeast, also weighed on volumes in the quarter, creating short‑term headwinds that management views as transitory.
Pathline Integration Dilutive Effects
While Pathline provides a strategic regional platform, its integration diluted gross margin in the quarter and required load‑balancing across the broader lab network. This operational shift reduced the volume directly attributed to Pathline, but executives framed it as a necessary step to optimize capacity and service levels over time.
Convertible Debt Maturity and Refinancing Needs
The capital structure adds another layer of risk, with roughly $342 million of convertible debt maturing in January 2028. NeoGenomics is working with banks and aims to refinance in the second half of 2026, leaving investors to monitor execution risk around future market conditions and the terms of any refinancing.
Dependence on NGS Adoption and Execution
A substantial portion of the company’s upside depends on sustaining strong NGS growth, with guidance assuming around 22% NGS growth excluding liquid biopsy. Any slowdown in adoption or delays in rolling out Epic Aura integrations and PanTracer LBx commercialization could pressure results, making flawless commercial execution critical.
Forward-Looking Guidance and Outlook
Looking ahead, NeoGenomics’ raised 2026 outlook calls for revenue of $797 million to $803 million, with a midpoint of $800 million and adjusted EBITDA of $55 million to $57 million, implying roughly 27% to 31% growth. The company expects about 100 basis points of gross margin expansion for the year, mid‑single‑digit million contributions from both RaDaR ST and PanTracer Liquid, and continued discipline on costs as it targets sustained double‑digit growth.
NeoGenomics’ earnings call painted a picture of a diagnostics company leaning into high‑growth NGS and liquid biopsy while managing through near‑term margin and nonclinical challenges. For investors, the key watchpoints will be the pace of NGS adoption, the ramp of RaDaR ST and PanTracer, and the eventual refinancing of the 2028 convertible, but for now the growth story appears intact and gaining traction.